Concarlo Holdings, LLC
Innovation for combating drug resistance and diagnosing the right drugs is a hallmark of Concarlo’s R&D mission and technologies. Concarlo Team: LisaMarie Casey
Read MoreAvatar Medical, LLC
Avatar is a molecular engineering company that is developing novel universal Influenza and RSV subunit vaccines, both representing $ multi-billion market opportunities with mitigated clinical risk. Avatar Team: Chris Marshall
Read MoreHemoGenyx, LLC
HemoGenyx is a preclinical-stage biotechnology company focused on the discovery, development and commercialisation of novel therapies and treatments for blood diseases, like leukemia and lymphoma. HemoGenyx Team: Vladislav Sandler
Read MoreParkside Scientific
New York City based Parkside Scientific develops novel “best-in-class” small molecule drugs that target bromodomain (BrD) proteins for epigenetic control of gene transcription in cancers and inflammatory disorders. Parkside Scientific Team: Gary Duberstein
Read MoreLucerna, Inc.
At Lucerna, we are developing new sets of research tools to study and exploit RNA the same way fluorescent proteins did for the protein field. Lucerna Team: Karen Wu
Read MoreMirimus
Mirimus is engaged in the design, development and pioneering of new genome editing technologies to develop animal models that are crucial for the preclinical evaluation of new therapeutics. Mirimus Team: Prem Premsrirut
Read MoreOverlai/TruClinic
Overlai/TruClinic Team: Alex Zoller
Read MoreCMP Scientific
CMP Scientific, Corp. is an analytical instrumentation company that provides capillary electrophoresis – mass spectrometry coupling interfaces to support therapeutics analysis for global biopharmaceutical companies. CMP Scientific Team: James Xia CMP Scientific was with The Next Milestone at the Downstate Incubator from 2016 to 2017.
Read MoreEpiBone, Inc.
We grow personalized living bone grafts in our lab, from patients own cells in the size and shape they need. EpiBone Team: Nina Tandon EpiBone has been with The Next Milestone at the Downstate Incubator since 2016.
Read More